1
                                                                    Exhibit 99.2

WARNER CHILCOTT COMPLETES ACQUISITION OF THREE BRANDED WOMEN'S HEALTHCARE
PHARMACEUTICALS FROM BRISTOL-MYERS SQUIBB

DUBLIN, Ireland and ROCKAWAY, N.J., Feb. 16/PRNewswire/ -- Warner Chilcott, plc
(Nasdaq: WCRX - news) today announced that it has completed the acquisition of
three branded women's healthcare pharmaceutical products from Bristol-Myers
Squibb Company (NYSE: BMY - news) for aggregate consideration of $180 million.
Warner Chilcott funded the acquisition through a 144A transaction of $200
million of Senior Notes due 2008.

As previously announced, the acquired products, which currently generate
approximately $50 million in annual revenues, are Estrace(R) vaginal cream, an
estrogen replacement therapy product, and two oral contraceptives, Ovcon(R) 35
and Ovcon(R) 50. Warner Chilcott has already been marketing two of these
products with measurable success since March 1999 under an existing agreement
with Bristol-Myers Squibb. As a result, management believes that their
integration into its product portfolio will be accomplished rapidly and with
few of the risks typically associated with new product acquisitions.

"This acquisition is truly an important milestone in our Company's history -- a
transaction that leverages our sales and marketing infrastructure, capitalizes
on our expertise in the women's healthcare market and transforms Warner Chilcott
into a solidly profitable enterprise. Estrace cream and the Ovcon brands are
well-recognized women's healthcare products in billion dollar markets with
significant growth opportunities. We are proud to add these brands to our strong
and growing women's healthcare product portfolio," said James G. Andress,
Chairman and Chief Executive Officer, Warner Chilcott, plc.

Warner Chilcott is a developer and marketer of prescription pharmaceutical
products in the United States, primarily focused on the women's health
therapeutic category. Through its national sales force of over 260
representatives, Warner Chilcott markets branded pharmaceutical products
directly to physician specialists across the country, particularly
obstetrician/gynecologists and urologists. The Company's principal offices are
in Dublin, Ireland and Rockaway, New Jersey.

Note:

Statements made in this press release include forward-looking statements made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995. Such statements, including those
   2
relating to financial expectations for the fiscal year 2000 and beyond, involve
certain risks and uncertainties that could cause actual results to differ
materially from those in the forward looking statements, including, but not
limited to, the company's dependence on key products, risks associated with
product development and manufacturing, the uncertainty of future financial
results and fluctuations in operating results, dependence on the companies'
acquisition strategy, new product introductions and other risks described from
time to time in the companies' SEC filings. These forward-looking statements
represent the judgment of the company, as of the date of this release, and the
company disclaims any intent or obligation to update these forward-looking
statements. Information on other significant potential risks and uncertainties
not discussed herein may be found in the Company's filings with the Securities
and Exchange Commission including its Form 10K for the year ended December 31,
1998 and Form 10Q for the quarter ended September 30, 1999.